President Donald Trump’s Day One executive order rescinding Biden-era Medicare and Medicaid price innovation programs signals sweeping changes to the drug and treatment pricing agency within the ...

Robert F. Kennedy Jr. (RFK Jr.) has been confirmed by the Senate as secretary of the Department of Health and Human Services (HHS). In this ...

The U.S. Food and Drug Administration (FDA ... Sign Up For Free » However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

In a statement released last week, the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs is a top priority for the Trump administration. CMS added that ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Popular weight loss drugs like ... been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said ...

President Donald Trump likely won't do away with a process that allows Medicare to negotiate ... threaten profits and discourage drug innovation. The Trump administration has offered few specifics ...

If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.